SCHEMBL2835482

SCHEMBL2835482

NC1CC1c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 15/20 0.60
MAOB P27338 12/20 0.60
KCNH2 Q12809 3/20 0.60
RCOR1 Q9UKL0 3/20 0.60
KDM1B Q8NB78 2/20 0.60
MAOA P21397 7/20 0.58
CYP2C19 P33261 4/20 0.58
CYP2B6 P20813 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
LMNA P02545 2/20 0.58
TAAR1 Q96RJ0 2/20 0.58
HTR2C P28335 2/20 0.58
CYP3A4 P08684 1/20 0.58
HTR1A P08908 1/20 0.58
ADRA2A P08913 1/20 0.58
CYP2A6 P11509 1/20 0.58
SLC6A2 P23975 1/20 0.58
ADRA1A P35348 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837243 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL7509170 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL6991920 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL7509163 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL6991918 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL31113844 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL1570164 0.98 KDM1A (0.61) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL2217941 0.98 KDM1A (0.61) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL19596183 0.93 KDM1A (0.67) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL530132 0.93 KDM1A (0.67) KDM1AMAOBKCNH2RCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121796368-A Tree shrew liver cancer modeling method 云南云科生物技术研究院 2026-04-07 CN disclosed
US-20250367143-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-12-04 US disclosed
US-20250367158-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-12-04 US disclosed
US-20250145561-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 RESEARCH TRIANGLE INSTITUTE (US) 2025-05-08 US disclosed
EP-4263492-B1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-04-09 EP disclosed
CN-119546577-A Modulators of G protein-coupled receptor 88 阿卡蒂亚药品公司 2025-02-28 CN disclosed
CN-119403782-A Modulators of G protein-coupled receptor 88 阿卡蒂亚药品公司 2025-02-07 CN disclosed
EP-4469431-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 Research Triangle Institute (US) 2024-12-04 EP disclosed
CN-118166004-B MRNA for encoding human PCCA or PCCB protein and use thereof 北京剂泰医药科技有限公司 2024-12-03 CN disclosed
CN-118541348-A 4-Substituted-phenylacetamides and aryl ureas as agonists of the orphan receptor GPR88 研究三角协会 2024-08-23 CN disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
EP-0946561-B1 TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS ASTRAZENECA AB (SE) 2002-02-13 EP disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed
US-6297232-B1 TREATMENT OF PLATELET AGGREGATION DISORDERS. ASTRAZENECA AB (SE) 2001-10-02 US disclosed
US-6251910-B1 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists ASTRAZENECA UK LIMITED (GB) 2001-06-26 US disclosed
CN-1270590-A Novel compounds ASTRA PHARMA PROD (GB) 2000-10-18 CN disclosed
EP-0996621-A1 NOVEL COMPOUNDS Astra Pharmaceuticals Limited (GB) 2000-05-03 EP disclosed
EP-0946561-A1 TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS Astra Pharmaceuticals Limited (GB) 1999-10-06 EP disclosed
WO-1999005143-A1 NOVEL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1999-02-04 WO disclosed
WO-1998028300-A1 TRIAZOLO[4,5-D]PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS ASTRA PHARMACEUTICALS LTD. (GB) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250367143-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 GPR88, GPR84, GPR68 KDM1A 3705/4885MAOB 1932/4885KCNH2 4302/4885
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 KDM1A 1587/4885MAOB 544/4885KCNH2 2800/4885
US-20250145561-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 GPR88, GPR84, GPR139 KDM1A 2125/4885MAOB 1329/4885KCNH2 2840/4885
US-20250367158-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 GPR88, GPR68, HTR2A KDM1A 2985/4885MAOB 1607/4885KCNH2 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.